Gland Pharma Limited and Neuland Laboratories Limited have entered into a long-term strategic Contract Development and Manufacturing Organization (CDMO) partnership to expand sterile Active Pharmaceutical Ingredient (API) manufacturing capabilities.
Under the agreement, Gland Pharma will establish a dedicated sterile manufacturing suite at its facility in Visakhapatnam to support Neuland’s growing demand for complex sterile APIs. Built and operated in compliance with cGMP, USFDA, and European regulatory standards, the new suite will add approximately 1,400 kg of annual production capacity.
The strategic collaboration targets high-value microparticle depot products advanced injectable formulations where drugs are encapsulated in tiny polymer particles to allow sustained, slow release and eliminate the need for frequent daily dosing. By combining Neuland’s deep expertise in complex API chemistry and process development with Gland Pharma’s global aseptic manufacturing infrastructure, the partners will offer an integrated CDMO platform covering development, scale-up, regulatory support, and commercial production.
“This investment expands our capabilities in sterile API manufacturing and supports increasing customer demand. By leveraging our complementary strengths, we will provide a robust and scalable CDMO solution,” stated Srinivas Sadu, Executive Chairman of Gland Pharma Limited.
Saharsh Davuluri, CEO and Managing Director of Neuland Laboratories, added, “Demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies. This partnership creates a differentiated platform to deliver the quality and supply assurance expected by global clients.”
The alliance enables both companies to capture high-value market segments efficiently without requiring Neuland to construct separate sterile production facilities.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
